Safe Reduction Of Radiotherapy Is The Aim Of Cancer Researchers

Main Category: Cancer / Oncology
Also Included In: Radiology / Nuclear Medicine;  Genetics
Article Date: 03 Oct 2007 - 3:00 PST

email to a friend   printer friendly   view / write opinions   rate article

University of Manchester scientists discussed their research aimed at reducing the side effects of radiotherapy without decreasing its effectiveness at the National Cancer Research Institute conference in Birmingham yesterday (Tuesday 2 October 2007).

Around half of patients receive radiotherapy as part of their cancer treatment but the dose is limited by the possibility of causing side effects (toxicity) to the normal tissues and organs that surround the tumour. Some patients are more likely to experience these side effects than others: that is, there is an individual variation in tissue response. Some patients will be very sensitive.

Dr Catharine West, of the University's Cancer Studies research group, and Dr Neil Burnet, of the University of Cambridge, are leading a large multi-centre UK study designed to identify the common genetic variations that are associated with such side effects. The study -- Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy (RAPPER) -- is funded by Cancer Research UK and aims to extract DNA from the blood samples of 2,200 patients with a variety of cancers.

Dr West explains: "This is a very exciting development in cancer research. Genotyping studies should provide a means of identifying radiosensitive patients and lead to a greater individualisation of radiation dose prescription to optimise tumour control while reducing toxicity."

Dr West and her team are also involved in a study of patients with soft tissue sarcoma (cancer in the muscles), a rare cancer that accounts for approximately 1% of adult cancers with around 1,200 cases in the UK each year, again funded by Cancer Research UK.

VORTEX -- led by Dr Martin Robinson at the University of Sheffield -- is a randomised trial to assess if reducing post-operative radiotherapy in patients with soft tissue sarcoma (cancer of the muscle) increases their limb function without compromising the treatment. The Manchester team are using samples from VORTEX to carry out VORTEX-BIOBANK, a study that aims to develop a tumour profile that will identify patients with an increased likelihood of secondary cancer. The team also aims to investigate associations between common genetic variation and a patient's risk of radiation induced side-effects in this particular cancer, as they are doing for a variety of other cancers in RAPPER.

Miss Rebecca Elliott, who will make a presentation about the team's work at the conference today, says: "There is exciting high-throughput technology out there and we are looking at the possibility of individualising patient treatment. The technology allows us to look at the variation and expression of genes to see which genes indicate who will be sensitive to radiotherapy. In future we will have a patient profile -- if you have certain versions of genes x, y and z, then you have the chance of getting toxicity one hundred times more than someone with other versions."

"Although we are still collecting samples and are some way off getting our final results, it is an important new pathway in cancer research."

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

The Cancer Studies research group is one of two in the School of Cancer and Imaging Sciences and is a key partner in the Manchester Cancer Research Centre as part of the Manchester Comprehensive Cancer Network. The Manchester Cancer Research Centre will see a major increase in the cancer research efforts and facilities with the aim to recruit at least ten world-class clinical and non-clinical cancer researchers within the next five years. The strong partnership with the University and Trusts will help make Manchester a truly formidable player in international cancer research and care. The Cancer Network provides a range of specialist diagnostics and treatment for cancer patients together with laboratory, translational and clinical research.

The University of Manchester's Faculty of Medical and Human Sciences boasts an annual research income of £51 million, almost a third of the University's total research income. There are 7,600 undergraduate students and 1,600 postgraduates on award-bearing courses. More students graduate each year from the School of Medicine than from any other medical school in the UK. There is a strong organisational capability for undertaking cross-faculty teaching and research activity in partnership with the public sector and industry. Excellent links also exist with the NHS in terms of undertaking pioneering medical and clinically based research. The Faculty is a key stakeholder in the Greater Manchester Research Alliance.

About Cancer Research UK

Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.

Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.

Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.

Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.

Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.

For further information visit http://www.cancerresearchuk.org/

The National Cancer Research Institute (NCRI) Cancer Conference is the UK's premier forum for disseminating advances across all aspects of cancer research.

AstraZeneca is the gold sponsor for the NCRI Cancer Conference 2007.

The National Cancer Research Institute (NCRI) was established in April 2001. It is a partnership between government, the voluntary sector and the private sector, with the primary mission of maximising patient benefit that accrues from cancer research in the UK through coordination of effort and joint planning towards an integrated national strategy for cancer research. See http://www.ncri.org.uk/.

The NCRI consists of: The Association of British Pharmaceutical Industry (ABPI); The Association for International Cancer Research; The Biotechnology and Biological Sciences Research Council; Breakthrough Breast Cancer; Breast Cancer Campaign; Cancer Research UK; Department of Health; Economic and Social Research Council; Leukaemia Research Fund; Ludwig Institute for Cancer Research; Macmillan Cancer Support; Marie Curie Cancer Care; The Medical Research Council; Northern Ireland Health and Personal Social Services Research & Development Office; Roy Castle Lung Cancer Foundation; Scottish Executive Health Department; Tenovus; Wales Office of Research and Development for Health & Social Care; Wellcome Trust; and Yorkshire Cancer Research.

Source: Mikaela Sitford
University of Manchester